Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-26 @ 12:46 AM
Study NCT ID:
NCT06834360
Status:
RECRUITING
Last Update Posted:
2025-11-28
First Post:
2025-02-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Sponsor:
Sanofi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-02-06
Start Date Type:
ACTUAL
Primary Completion Date:
2027-01-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-13
Completion Date Type:
ESTIMATED
First Submit Date:
2025-02-14
First Submit QC Date:
None
Study First Post Date:
2025-02-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-25
Last Update Post Date:
2025-11-28
Last Update Post Date Type:
ESTIMATED